Skip to search formSkip to main contentSkip to account menu

Wy 41770

Known as: Wy-41,770, Wy-41770 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AcetatesDibenzocycloheptenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1988
1988
Mucosal Lesions Induced in the Rat Intestinal Tract by the Anti-Inflammatory Drug, Wy-41,770, a Weak Inhibitor of Prostaglandin Synthesis, Contrasted with Those from the Potent Prostaglandin…
  • K. Rainsford
  • Toxicologic pathology (Print)
  • 1988
  • Corpus ID: 2466983
The intestinal ulcerogenic activity of the weak prostaglandin synthesis inhibitor drug Wy-41,770 [5H-dibenzo(a,d)-cyclohepten-5… 
1986
1986
Immunomodulating activity of Wy-41,770 (5H-dibenzo[A,D]cyclohepten-5-ylidene) acetic acid.
The immunomodulatory effects of Wy-41,770 (5H-dibenzo[a,d]cyclohepten-5-ylidene) acetic acid, were compared to levamisole and… 
1984
1984
The antiinflammatory profile of (5H-dibenzo[A, D]-cyclohepten-5-ylidene)acetic acid (WY-41,770), an agent possessing weak prostaglandin synthetase inhibitory activity that is devoid of gastric side…
Wy-41,770 [(5H-dibenzo[a,d]cyclohepten-5-ylidene)acetic acid], a novel acrylic acid, was compared to indomethacin and aspirin in… 
1984
1984
The absence of antibodies to type II collagen in established adjuvant arthritis in rats
Utilizing an adjuvant arthritis model in rats, we examined humoral immunity to collagen and inflammation in animals with active… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)